Skip to main content

Table 2 Antidiabetic pharmacotherapy at baseline before therapy adjustment per age group (combinations with a proportion < 1% were omitted)

From: Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia

  Age ≥ 70 years Age < 70 to ≥ 60 years Age < 60 years p-value*
  n=1,373, (%) n=1,184, (%) n=1,253, (%)
  n % n % n %  
Oral monotherapy 973 70.9 777 65.6 867 69.2 0.32
 Metformin 700 51.0 616 52.0 751 59.9 <0.0001
 Sulfonylureas 205 14.9 101 8.5 81 6.5 <0.0001
 Glucosidase inhibitors 27 2.0 22 1.9 15 1.2 0.13
 Glinides 29 2.1 23 1.9 9 0.7 <0.01
 Thiazolidinediones 5 0.4 11 0.9 6 0.5 0.66
 DPP-4 inhibitors 7 0.5 4 0.3 5 0.4 0.65
Oral dual combination 400 29.1 407 34.4 386 30.8 0.32
 Met + SU 251 18.3 232 19.6 183 14.6 <0.05
 Met + Glukos 12 0.9 12 1.0 6 0.5 0.26
 Met + Glin 27 2.0 39 3.3 37 3.0 0.11
 Met + Glitaz 47 3.4 62 5.2 75 6.0 <0.01
 Met + DPP-4 inhibitors 39 2.8 49 4.1 63 5.0 <0.01
  1. Legend. DPP-4, Dipeptidyl-peptidase 4 inhibitors; OAD, oral antidiabetic drug; * Cochran-Armitage or Jonchkheere-Terpstra test; No GLP-1 analogues or insulins were prescribed because patients with these antidiabetic drugs at baseline were excluded by the study protocol[12].